MannKind | MNKD - Ebitda


MannKind reported $9.75M in EBITDA for its fiscal quarter ending in June of 2025.





Ebitda Change Date
Adma Biologics USD 58.74M 14.75M Sep/2025
Dynavax Technologies USD 35.53M 10.9M Sep/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Halozyme Therapeutics USD 248.25M 22.74M Sep/2025
Insmed USD -297.13M 71.11M Jun/2025
MacroGenics USD 21.95M 55.39M Sep/2025
MannKind USD 9.75M 17.66M Jun/2025
Merck USD 8.39B 1.97B Sep/2025
Novo Nordisk DKK 31.44B 6.84B Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Sanofi EUR 4.84B 2.95B Sep/2025
Xencor USD -30.52M 6.39M Jun/2025